缓解转换驱动多发性骨髓瘤CAR-T治疗后的结局:DRST登记分析
该登记分析纳入德国343例三重暴露的复发难治多发性骨髓瘤患者,接受ide-cel(n=266)或cilta-cel(n=77)治疗。cilta-cel较ide-cel总缓解率更高(94% vs 82%),10个月无进展生存率更高(76% vs 47%),完全缓解率更高(61% vs 39%),倾向评分匹配后加权多变量分析确认cilta-cel的PFS优势(HR 0.48)。
要点
- cilta-cel较ide-cel总缓解率更高(94% vs 82%),10个月PFS更高(76% vs 47%)。
- cilta-cel完全缓解率更高(61% vs 39%),更多患者从低于完全缓解转换为完全缓解。
- cilta-cel的ICANS更常见(25% vs 15%),10个月非复发死亡率两组相当(7% vs 5%)。
核心结论
- cilta-cel较ide-cel表现出更强的缓解转换能力和持久缓解,结局与各自获批的关键试验相当,提示需个体化选择CAR-T治疗以优化患者结局。
研究设计与样本
- 登记分析,纳入德国343例三重暴露的复发难治多发性骨髓瘤患者,均接受过>3线既往治疗,接受ide-cel(n=266)或cilta-cel(n=77)治疗。
主要发现
- cilta-cel组总缓解率为94%,ide-cel组为82%。
- cilta-cel组10个月无进展生存率为76%,ide-cel组为47%。
- cilta-cel组完全缓解率为61%,ide-cel组为39%。
- cilta-cel组细胞因子释放综合征发生率为85%,ide-cel组为81%,以低级别为主。
- cilta-cel组免疫效应细胞相关神经毒性综合征发生率为25%,ide-cel组为15%;10个月非复发死亡率cilta-cel组为7%,ide-cel组为5%。
关键数值与推荐
- 倾向评分匹配后加权多变量分析显示cilta-cel在PFS方面具有显著优势,风险比为0.48。
- 对于治疗后达到完全缓解的患者,cilta-cel显示出更长的PFS,尤其是治疗前仅达部分缓解或更差的患者。
临床怎么用
- 作者认为,这些发现强调需要个体化选择CAR-T治疗以优化患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class-exposed patients with relapsed and refractory multiple myeloma who received idecabtagene vicleucel (ide-cel; n = 266) or ciltacabtagene autoleucel (cilta-cel; n = 77) after >3 previous lines of therapy in Germany. Cilta-cel, compared with ide-cel, demonstrated superior outcomes, achieving a higher overall response rate (94% vs 82%) and 10-month progression-free survival (PFS; 76% vs 47%). Cilta-cel also led to higher complete response (CR; 61% vs 39%) and improved response conversion, with more patients achieving CR after starting from less than CR before chimeric antigen receptor T-cell (CAR T) therapy. For those attaining CR after therapy, cilta-cel showed longer PFS, especially in patients who entered treatment with a partial response or worse. Cytokine release syndrome was observed in 85% of cilta-cel and 81% of ide-cel cases, predominantly low grade. Immune effector cell-associated neurotoxicity syndrome was more common with cilta-cel (25% vs 15%), although nonrelapse mortality at 10 months was comparable between therapies (7% vs 5%). Weighted multivariable analysis after propensity score matching confirmed a significant advantage in terms of PFS for cilta-cel, with a hazard ratio of 0.48. Overall, outcomes in our registry analysis were comparable with the pivotal trials that led to approval of the respective agents. Cilta-cel demonstrated a greater capacity for response conversion and durable remission. These findings underscore the need for individualized CAR T therapy selection to optimize patient outcomes.
引用
- Merz M, Gagelmann N, Smaili S, et al. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood. 2025. PMID: 40504993. doi:10.1182/blood.2025028330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。